MEDTECH

articles with this tag

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

Thanks for subscribing!

X